ES2767651T3 - Composiciones antibacterianas que comprenden nanopartículas de oxo-hidróxido de cobre y su preparación - Google Patents
Composiciones antibacterianas que comprenden nanopartículas de oxo-hidróxido de cobre y su preparación Download PDFInfo
- Publication number
- ES2767651T3 ES2767651T3 ES16717670T ES16717670T ES2767651T3 ES 2767651 T3 ES2767651 T3 ES 2767651T3 ES 16717670 T ES16717670 T ES 16717670T ES 16717670 T ES16717670 T ES 16717670T ES 2767651 T3 ES2767651 T3 ES 2767651T3
- Authority
- ES
- Spain
- Prior art keywords
- copper
- nanoparticles
- oxo
- composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 207
- 239000000203 mixture Substances 0.000 title claims abstract description 132
- VTGNXADCFUDPLG-UHFFFAOYSA-N O(O)O.[Cu] Chemical compound O(O)O.[Cu] VTGNXADCFUDPLG-UHFFFAOYSA-N 0.000 title claims abstract description 96
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title description 9
- 239000010949 copper Substances 0.000 claims abstract description 190
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 145
- 229910052802 copper Inorganic materials 0.000 claims abstract description 145
- 239000003446 ligand Substances 0.000 claims abstract description 120
- 238000011282 treatment Methods 0.000 claims abstract description 50
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229910001431 copper ion Inorganic materials 0.000 claims abstract description 27
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 21
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 16
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 15
- 206010052428 Wound Diseases 0.000 claims abstract description 14
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 37
- 238000000576 coating method Methods 0.000 claims description 33
- 239000000758 substrate Substances 0.000 claims description 26
- 230000002265 prevention Effects 0.000 claims description 25
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 24
- 238000004090 dissolution Methods 0.000 claims description 24
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 20
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 20
- 241000588724 Escherichia coli Species 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 230000008569 process Effects 0.000 claims description 19
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 18
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 18
- 230000009036 growth inhibition Effects 0.000 claims description 18
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 18
- 239000011159 matrix material Substances 0.000 claims description 18
- 230000000813 microbial effect Effects 0.000 claims description 18
- 239000007790 solid phase Substances 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 17
- 238000003556 assay Methods 0.000 claims description 15
- 235000002906 tartaric acid Nutrition 0.000 claims description 15
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 14
- 235000011037 adipic acid Nutrition 0.000 claims description 14
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 13
- 239000011975 tartaric acid Substances 0.000 claims description 13
- 239000001361 adipic acid Substances 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 12
- 210000004400 mucous membrane Anatomy 0.000 claims description 11
- 229940095064 tartrate Drugs 0.000 claims description 11
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 10
- 239000000174 gluconic acid Substances 0.000 claims description 10
- 235000012208 gluconic acid Nutrition 0.000 claims description 10
- 241000894007 species Species 0.000 claims description 10
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 108010024636 Glutathione Proteins 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 6
- 229960003180 glutathione Drugs 0.000 claims description 6
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 5
- 241000222122 Candida albicans Species 0.000 claims description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 239000000084 colloidal system Substances 0.000 claims description 5
- 229940050410 gluconate Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- 241001147693 Staphylococcus sp. Species 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- 241000488157 Escherichia sp. Species 0.000 claims description 3
- 206010017533 Fungal infection Diseases 0.000 claims description 3
- 238000004566 IR spectroscopy Methods 0.000 claims description 3
- 241000588754 Klebsiella sp. Species 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 241000191938 Micrococcus luteus Species 0.000 claims description 3
- 241000191936 Micrococcus sp. Species 0.000 claims description 3
- 208000031888 Mycoses Diseases 0.000 claims description 3
- 241000589774 Pseudomonas sp. Species 0.000 claims description 3
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 3
- 241000194022 Streptococcus sp. Species 0.000 claims description 3
- 210000002615 epidermis Anatomy 0.000 claims description 3
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 3
- 239000012429 reaction media Substances 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 241000588625 Acinetobacter sp. Species 0.000 claims description 2
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 claims description 2
- 241001495184 Chlamydia sp. Species 0.000 claims description 2
- 241000193163 Clostridioides difficile Species 0.000 claims description 2
- 241000193464 Clostridium sp. Species 0.000 claims description 2
- 241000192125 Firmicutes Species 0.000 claims description 2
- 241000187488 Mycobacterium sp. Species 0.000 claims description 2
- 241000607149 Salmonella sp. Species 0.000 claims description 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 2
- 241000607284 Vibrio sp. Species 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 229950006191 gluconic acid Drugs 0.000 claims 2
- 229960001367 tartaric acid Drugs 0.000 claims 2
- 241000588626 Acinetobacter baumannii Species 0.000 claims 1
- 229960000250 adipic acid Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 150000002763 monocarboxylic acids Chemical class 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 description 45
- 239000012071 phase Substances 0.000 description 33
- 230000012010 growth Effects 0.000 description 31
- 230000000845 anti-microbial effect Effects 0.000 description 29
- 239000002245 particle Substances 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 25
- 239000000725 suspension Substances 0.000 description 22
- 229910016344 CuSi Inorganic materials 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 230000003115 biocidal effect Effects 0.000 description 20
- 229910021645 metal ion Inorganic materials 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 19
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 18
- 238000009826 distribution Methods 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 18
- 239000002609 medium Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 150000001879 copper Chemical class 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 description 15
- 235000010755 mineral Nutrition 0.000 description 15
- 239000011707 mineral Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- 229910052751 metal Inorganic materials 0.000 description 14
- 239000002184 metal Substances 0.000 description 14
- JJLJMEJHUUYSSY-UHFFFAOYSA-L Copper hydroxide Chemical class [OH-].[OH-].[Cu+2] JJLJMEJHUUYSSY-UHFFFAOYSA-L 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical class OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- -1 carboxylate anion Chemical class 0.000 description 11
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000002296 dynamic light scattering Methods 0.000 description 11
- 239000011164 primary particle Substances 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 229910001956 copper hydroxide Inorganic materials 0.000 description 10
- 238000011321 prophylaxis Methods 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 238000001556 precipitation Methods 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000005750 Copper hydroxide Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000004745 nonwoven fabric Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000007993 MOPS buffer Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 208000004210 Pressure Ulcer Diseases 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- 206010021639 Incontinence Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 206010048038 Wound infection Diseases 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 238000005054 agglomeration Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 208000010247 contact dermatitis Diseases 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 150000004706 metal oxides Chemical class 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 235000012976 tarts Nutrition 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003929 acidic solution Substances 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229910044991 metal oxide Inorganic materials 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 208000034493 Mucous membrane disease Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 239000004115 Sodium Silicate Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000823609 Staphylococcus aureus subsp. aureus RN4220 Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001279 adipic acids Chemical class 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 229940124447 delivery agent Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 description 2
- 150000004692 metal hydroxides Chemical class 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000011858 nanopowder Substances 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001350 scanning transmission electron microscopy Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 2
- 229910052911 sodium silicate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000007817 turbidimetric assay Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 244000034356 Aframomum angustifolium Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010051548 Burn infection Diseases 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 239000005749 Copper compound Substances 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241001441571 Hiodontidae Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000784732 Lycaena phlaeas Species 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 1
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000235088 Saccharomyces sp. Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000120737 Viscum fischeri Species 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001340 alkali metals Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000002802 antimicrobial activity assay Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 150000001880 copper compounds Chemical class 0.000 description 1
- MPTQRFCYZCXJFQ-UHFFFAOYSA-L copper(II) chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Cu+2] MPTQRFCYZCXJFQ-UHFFFAOYSA-L 0.000 description 1
- QUQFTIVBFKLPCL-UHFFFAOYSA-L copper;2-amino-3-[(2-amino-2-carboxylatoethyl)disulfanyl]propanoate Chemical compound [Cu+2].[O-]C(=O)C(N)CSSCC(N)C([O-])=O QUQFTIVBFKLPCL-UHFFFAOYSA-L 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000021112 essential micronutrients Nutrition 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000010442 halite Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 239000008235 industrial water Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 238000011235 metanalysis Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000007966 viscous suspension Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1507002.2A GB201507002D0 (en) | 2015-04-24 | 2015-04-24 | Copper Oxo-hydroxide nanoparticles and their uses as biocidal agents |
| PCT/EP2016/059074 WO2016170152A1 (en) | 2015-04-24 | 2016-04-22 | Antibacterial compositions comprising copper oxo-hydroxide nanoparticles and their uses as biocidal agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2767651T3 true ES2767651T3 (es) | 2020-06-18 |
Family
ID=53488605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16717670T Active ES2767651T3 (es) | 2015-04-24 | 2016-04-22 | Composiciones antibacterianas que comprenden nanopartículas de oxo-hidróxido de cobre y su preparación |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20180147177A1 (https=) |
| EP (1) | EP3285759B1 (https=) |
| JP (1) | JP6775523B2 (https=) |
| CN (1) | CN108064152B (https=) |
| CA (1) | CA2983651A1 (https=) |
| ES (1) | ES2767651T3 (https=) |
| GB (1) | GB201507002D0 (https=) |
| SG (1) | SG11201708618WA (https=) |
| WO (1) | WO2016170152A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3789046A1 (en) | 2019-09-05 | 2021-03-10 | Nanordica Medical Oü | Biocompatible nanoparticles with various surface functionalization for antimicrobial applications |
| US20240081336A1 (en) * | 2019-09-16 | 2024-03-14 | Corning Incorporated | Color stabilization of biocidal coatings |
| US11559774B2 (en) | 2019-12-30 | 2023-01-24 | Marathon Petroleum Company Lp | Methods and systems for operating a pump at an efficiency point |
| CA3104319C (en) | 2019-12-30 | 2023-01-24 | Marathon Petroleum Company Lp | Methods and systems for spillback control of in-line mixing of hydrocarbon liquids |
| US10990114B1 (en) | 2019-12-30 | 2021-04-27 | Marathon Petroleum Company Lp | Methods and systems for inline mixing of hydrocarbon liquids |
| US11607654B2 (en) | 2019-12-30 | 2023-03-21 | Marathon Petroleum Company Lp | Methods and systems for in-line mixing of hydrocarbon liquids |
| GB202005054D0 (en) * | 2020-04-06 | 2020-05-20 | Nemysis Ltd | Carboxylate Ligand Modified Ferric Iron Hydroxide Compositions for Use in the Treatment or Prevention of Iron Deficiency Associated with Liver Diseases |
| CN111592032A (zh) * | 2020-05-09 | 2020-08-28 | 山东科技大学 | 抗菌氢氧化铜纳米线膜及其制备方法及其二次利用方法 |
| US12589166B2 (en) | 2020-05-15 | 2026-03-31 | Rutgers, The State University Of New Jersey | Compositions and methods for treating wounds |
| US12012883B2 (en) | 2021-03-16 | 2024-06-18 | Marathon Petroleum Company Lp | Systems and methods for backhaul transportation of liquefied gas and CO2 using liquefied gas carriers |
| US11655940B2 (en) | 2021-03-16 | 2023-05-23 | Marathon Petroleum Company Lp | Systems and methods for transporting fuel and carbon dioxide in a dual fluid vessel |
| US11578836B2 (en) | 2021-03-16 | 2023-02-14 | Marathon Petroleum Company Lp | Scalable greenhouse gas capture systems and methods |
| US11578638B2 (en) | 2021-03-16 | 2023-02-14 | Marathon Petroleum Company Lp | Scalable greenhouse gas capture systems and methods |
| US11447877B1 (en) | 2021-08-26 | 2022-09-20 | Marathon Petroleum Company Lp | Assemblies and methods for monitoring cathodic protection of structures |
| US12129559B2 (en) | 2021-08-26 | 2024-10-29 | Marathon Petroleum Company Lp | Test station assemblies for monitoring cathodic protection of structures and related methods |
| US12043905B2 (en) | 2021-08-26 | 2024-07-23 | Marathon Petroleum Company Lp | Electrode watering assemblies and methods for maintaining cathodic monitoring of structures |
| US12180597B2 (en) | 2021-08-26 | 2024-12-31 | Marathon Petroleum Company Lp | Test station assemblies for monitoring cathodic protection of structures and related methods |
| US11686070B1 (en) | 2022-05-04 | 2023-06-27 | Marathon Petroleum Company Lp | Systems, methods, and controllers to enhance heavy equipment warning |
| CN116237532A (zh) * | 2022-12-22 | 2023-06-09 | 江南大学 | 一种糖基配体类似物诱导手性钴基超小纳米粒子的合成方法 |
| US12012082B1 (en) | 2022-12-30 | 2024-06-18 | Marathon Petroleum Company Lp | Systems and methods for a hydraulic vent interlock |
| US12043361B1 (en) | 2023-02-18 | 2024-07-23 | Marathon Petroleum Company Lp | Exhaust handling systems for marine vessels and related methods |
| US12006014B1 (en) | 2023-02-18 | 2024-06-11 | Marathon Petroleum Company Lp | Exhaust vent hoods for marine vessels and related methods |
| CN116496301A (zh) * | 2023-04-06 | 2023-07-28 | 青岛科技大学 | 咔唑衍生物-金属氧化物纳米粒及其制备方法和应用 |
| US12297965B2 (en) | 2023-08-09 | 2025-05-13 | Marathon Petroleum Company Lp | Systems and methods for mixing hydrogen with natural gas |
| US12220492B1 (en) | 2023-09-08 | 2025-02-11 | King Faisal University | Wound dressing based on polymeric mixture of cellulose acetate and hyaluronic acid embedded with copper oxide and magnesium oxide nanoparticles |
| US12597151B2 (en) | 2023-09-18 | 2026-04-07 | Marathon Petroleum Company Lp | Systems and methods to determine vegetation encroachment along a right-of-way |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164367A (en) * | 1990-03-26 | 1992-11-17 | Procyte Corporation | Method of using copper(ii) containing compounds to accelerate wound healing |
| CA2431651A1 (en) * | 2000-11-16 | 2002-05-23 | Kenneth T. Zeiler | Antifungal nail composition and method of use |
| KR20080098582A (ko) * | 2005-11-17 | 2008-11-11 | 레메디 리서치 리미티드 | 병원균 조절 생성물 |
| JP2009535326A (ja) * | 2006-04-24 | 2009-10-01 | エヌエム・テク・リミテッド・ナノマテリアルズ・アンド・マイクロディバイシイズ・テクノロジー | 抗菌活性および抗ウイルス活性を有する機能的ナノ材料 |
| US20080147019A1 (en) * | 2006-12-19 | 2008-06-19 | Kimberly-Clark Worldwide, Inc. | Antimicrobial component system containing metallic nanoparticles and chitosan and/or its derivatives |
| GB0702270D0 (en) * | 2007-02-06 | 2007-03-14 | Medical Res Council | Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation |
| JP5756598B2 (ja) * | 2007-02-06 | 2015-07-29 | メディカル リサーチ カウンシル | リガンド修飾ポリオキソヒドロキシ金属イオン物質、それらの使用およびそれらの調製方法 |
| IT1391668B1 (it) * | 2008-07-23 | 2012-01-17 | Universita' Degli Studi Di Trieste | Materiali nanocompositi basati su nanoparticelle metalliche stabilizzate con polisaccaridi a struttura ramificata. |
| AU2010315083B2 (en) * | 2009-11-06 | 2015-10-08 | Carefusion 2200, Inc. | Copper salts of ion exchange materials for use in the treatment and prevention of infections |
| GB201101299D0 (en) * | 2011-01-25 | 2011-03-09 | Medical Res Council | Oxygen sensors and their uses |
| CN102631699A (zh) * | 2011-02-11 | 2012-08-15 | 佛山市优特医疗科技有限公司 | 含有纳米金属的抗菌性纤维类敷料及其制备方法 |
| SG194862A1 (en) * | 2011-05-24 | 2013-12-30 | Agienic Inc | Compositions and methods for antimicrobial metal nanoparticles |
| GB201207617D0 (en) * | 2012-05-02 | 2012-06-13 | Systagenix Wound Man Ip Co Bv | Wound dressings |
| US9255449B2 (en) * | 2012-07-30 | 2016-02-09 | Baker Hughes Incorporated | Drill bit with electrohydraulically adjustable pads for controlling depth of cut |
| US10398733B2 (en) * | 2013-03-15 | 2019-09-03 | Cda Research Group, Inc. | Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body |
| GB201402672D0 (en) * | 2014-02-14 | 2014-04-02 | Medical Res Council | Materials and methods relating to stabilised polymeric silicate compositions |
-
2015
- 2015-04-24 GB GBGB1507002.2A patent/GB201507002D0/en not_active Ceased
-
2016
- 2016-04-22 WO PCT/EP2016/059074 patent/WO2016170152A1/en not_active Ceased
- 2016-04-22 CN CN201680037392.6A patent/CN108064152B/zh not_active Expired - Fee Related
- 2016-04-22 SG SG11201708618WA patent/SG11201708618WA/en unknown
- 2016-04-22 EP EP16717670.0A patent/EP3285759B1/en active Active
- 2016-04-22 JP JP2017555479A patent/JP6775523B2/ja not_active Expired - Fee Related
- 2016-04-22 CA CA2983651A patent/CA2983651A1/en not_active Abandoned
- 2016-04-22 ES ES16717670T patent/ES2767651T3/es active Active
- 2016-04-22 US US15/567,419 patent/US20180147177A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180147177A1 (en) | 2018-05-31 |
| WO2016170152A1 (en) | 2016-10-27 |
| JP2018513186A (ja) | 2018-05-24 |
| SG11201708618WA (en) | 2017-11-29 |
| JP6775523B2 (ja) | 2020-10-28 |
| CA2983651A1 (en) | 2016-10-27 |
| EP3285759B1 (en) | 2019-11-13 |
| EP3285759A1 (en) | 2018-02-28 |
| GB201507002D0 (en) | 2015-06-10 |
| HK1245642A1 (en) | 2018-08-31 |
| CN108064152A (zh) | 2018-05-22 |
| CN108064152B (zh) | 2021-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2767651T3 (es) | Composiciones antibacterianas que comprenden nanopartículas de oxo-hidróxido de cobre y su preparación | |
| Mahmoud et al. | Gold nanoparticles loaded into polymeric hydrogel for wound healing in rats: Effect of nanoparticles’ shape and surface modification | |
| Morsy et al. | Development of hydroxyapatite-chitosan gel sunscreen combating clinical multidrug-resistant bacteria | |
| US10016525B2 (en) | Antimicrobial compositions for use in wound care products | |
| Hassanen et al. | In vivo and in vitro assessments of the antibacterial potential of chitosan-silver nanocomposite against methicillin-resistant Staphylococcus aureus–induced infection in rats | |
| US20080044491A1 (en) | Metal-containing formulations and methods of use | |
| CN1089587C (zh) | 稳定的交联聚乙烯吡咯烷酮和碘的配合物以及制备该配合物的方法 | |
| US7147845B2 (en) | Antimicrobial silver ion complex resinates | |
| JP2010506974A5 (https=) | ||
| US20250114398A1 (en) | Coated medicinal clay compositions, pharmaceutical compositions, and delivery of cation sources and methods of use thereof | |
| Athauda et al. | Enhanced bactericidal effects and drug delivery with gentamicin-conjugated nanoparticles | |
| Sun et al. | Fabrication of functionalized chitosan hydrogels triggered by charge interactions and pH response for bacterial capture and killing | |
| US11000502B2 (en) | Antimicrobial compositions comprising copper-hydroxypyrone complexes | |
| US6923990B2 (en) | Stabilized silver-ion amine complex compositions and methods | |
| HK1245642B (en) | Antibacterial compositions comprising copper oxo-hydroxide nanoparticles and their preparation | |
| Dugal et al. | Novel drug delivery system for management of S. Aureus infections in patients suffering venous stasis ulcers | |
| Keluo et al. | pH-Responsive ZnO Nanocarriers Functionalized with Curcumin for the Dual-Action Treatment of Inflammatory Oxidative Stress and Bacterial Colonization | |
| Herimatha et al. | Clarithromycin Loaded Chitosan Nanoparticles: Development and Characterization | |
| Jha | FORMULATION AND EVALUATION OF SULFADIAZINE LOADED SILVER NANOPARTICLES | |
| CZ2017318A3 (cs) | Antibakteriální a antifungální hydrofilní gelová kompozice na bázi zesíťovaného kopolymeru 2-hydroxyethylmethakrylátu |